The Top 10 Drugs Launches In 2019

The top 10 drugs which launches in 2019 are Ultomiris, Upadacitinib, Skyrizi, Zunteglo, Roxadustat, AR 101, Zolgensma, Brolucizumab, Spravato, and Mayzent. In 2019 the category of top 10 drug launches shows the thriving of exclusive urchin drugs which are based on novel technologies, also the endless passion is about the increasing immunology market whose chance is apparent in the world's best-selling drug.

  1. Ultomiris

This drug is launched by the Alexion company for paroxysmal nocturnal hemoglobinuria disease. The generic name of Ultomiris is ravulizumab- cwvz. The sale of Ultomiris estimated upto 2024 is $ 3.48 billion.

  1. Upadacitinib

This drug is launched by the AbbVie company for rheumatoid arthritis disease. The generic name of Upadacitinib is Upadacitinib. The sale of Upadacitinib estimated upto 2024 is $ 2.18 billion.

  1. Skyrizi

This drug is launched by the AbbVie company for psoriasis disease. The generic name of Skyrizi is risankizumab. The sale of Skyrizi estimated upto 2024 is $ 2.1 billion.

  1. Zunteglo

This drug is launched by the Bluebird Bio company for beta thalassemia disease. The sale of Zunteglo estimated upto 2024 is $ 1.87 billion.

  1. Roxadustat

This drug is launched by the AbbVie company for psoriasis disease. The generic name of Roxadustat is risankizumab. The sale of Roxadustat estimated upto 2024 is $ 2.1 billion

  1. AR 101

This drug is launched by the Aimmune Therapeutics company for peanut allergy disease. The sale of AR101 estimated upto 2024 is $ 1.75 billion

  1. Zolgensma

This drug is launched by the Novartis company for spinal muscular atrophy disease. The generic name of Zolgensma is onasemnogene abeparvovec. The sale of Zolgensma estimated upto 2024 is $ 1.56 billion

  1. Brolucizumab

This drug is launched by the Novartis company for wet age-related macular degeneration disease. The generic name of Brolucizumab is brolucizumab. The sale of Brolucizumab estimated upto 2024 is $ 1.38 billion

  1. Spravato

This drug is launched by the Johnson & Johnson company for major depressive disorder disease. The generic name of Spravato is esketamine. The sale of Spravato estimated upto 2024 is $ 1.30 billion

  1. Mayzent

This drug is launched by the Novartis company for secondary progressive multiple sclerosis disease. The generic name of Mayzent is siponimod. The sale of Mayzent estimated upto 2024 is $ 1.30 billion